Ibrutinib and ibrutinib: different names, same drug

Although in the pharmaceutical world a drug may have multiple names, the situation with ibrutinib and ibrutinib is somewhat unique. The two are actually two names for the same anti-cancer drug, and there is no substantial difference. Whether it is ibrutinib, ibrutinib, or its original English name Ibrutinib, they all refer to the same drug with significant anti-cancer effects, and Imbruvica is the well-known trade name of this drug.

This drug, as an oral small molecule tyrosine kinase inhibitor, mainly works by inhibitingBruton tyrosine kinase (BTK) activity. BTK is a key enzyme in the B cell receptor signaling pathway, and ibrutinib can precisely block this pathway, thereby effectively curbing the proliferation and survival of malignant B cells. This makes ibrutinib an important drug for the treatment of lymphomas and leukemias, particularly conditions such as chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenstrom's macroglobulinemia (WM), and chronic graft-versus-host disease (cGVHD).

However, like other powerful drugs, the use of ibrutinib can be associated with a range of side effects. Common ones include bleeding, increased risk of infection, atrial fibrillation, hypertension, decreased neutrophil count, and diarrhea. The manifestation and severity of these side effects vary from individual to individual. Therefore, when using ibrutinib, doctors will develop an appropriate treatment plan based on the patient's specific condition and closely monitor the patient's response during the treatment process in order to adjust the treatment strategy in a timely manner.

In general, ibrutinib and ibrutinib are actually different names for the same drug. They are completely consistent in terms of chemical composition, mechanism of action, treatment indications, and possible side effects.